FDA to review decison to end of Zepbound shortage (NYSE:LLY)

The U.S. Food and Drug Administration (FDA) has agreed to reconsider its decision to remove tirzepatide, the active ingredient of Eli Lilly’s (NYSE:LLY) diabetes therapy Mounjaro and weight loss therapy Zepbound, from its shortage list.

In connection with a lawsuit